RT Journal Article
SR Electronic
T1 Adjuvant Therapy for Salivary Gland Carcinomas
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4165
OP 4170
VO 36
IS 8
A1 MUTLAY SAYAN
A1 PRASHANT VEMPATI
A1 BRETT MILES
A1 MARITA TENG
A1 ERIC GENDEN
A1 ELIZABETH G. DEMICCO
A1 KRZYSZTOF MISIUKIEWICZ
A1 MARSHALL POSNER
A1 VISHAL GUPTA
A1 RICHARD L. BAKST
YR 2016
UL http://ar.iiarjournals.org/content/36/8/4165.abstract
AB Aim: We compared the clinical outcomes and toxicity profile among a retrospective cohort of patients with primary major salivary gland carcinomas (SGCs) treated with surgery followed by adjuvant radiation therapy (S+RT) versus surgery and adjuvant chemoradiotherapy (S+CRT). Patients and Methods: Twenty patients (71%) underwent S+RT and eight (29%) S+CRT at our Institution between 2006 and 2015. Microscopic positive margins were present in 54% of the patients. Results: The 3-year overall survival (OS) was 100% with S+RT and 87.5% with S+CRT (p=0.141) and locoregional control (LRC) was 95% with S+RT and 87.5% with S+CRT (p=0.383). There were no significant differences in the rate of acute (p=0.801) and late (p=0.714) toxicities. Conclusion: While we await randomized data, adjuvant CRT may be considered as a viable therapeutic option for patients at high-risk of local or regional recurrence, especially in those with a positive microscopic margin where further surgery may result in functional cranial neuropathies.